LV10505B - Method for the production of erytropoietin - Google Patents

Method for the production of erytropoietin Download PDF

Info

Publication number: LV10505B
Authority: LV; Latvia
Prior art keywords: die; der; epo; das; von
Prior art date: 1984-12-04

Application number

LVP-93-500A

Other languages

English (en)

Latvian (lv)

Other versions

LV10505A (lv

Inventor

Edward Fritsch

Rodney M Hewick

Kenneth Jacobs

Original Assignee

Genetics Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-12-04

Filing date

1993-06-08

Publication date

1996-04-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27418329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10505(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-06-08 Application filed by Genetics Inst filed Critical Genetics Inst

1995-02-20 Publication of LV10505A publication Critical patent/LV10505A/xx

1996-04-20 Publication of LV10505B publication Critical patent/LV10505B/lv

Links

102000003951 Erythropoietin Human genes 0.000 description 106
108090000394 Erythropoietin Proteins 0.000 description 106
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 106
229940105423 erythropoietin Drugs 0.000 description 105
239000012634 fragment Substances 0.000 description 65
239000013612 plasmid Substances 0.000 description 55
108020004414 DNA Proteins 0.000 description 41
108090000623 proteins and genes Proteins 0.000 description 28
239000013598 vector Substances 0.000 description 27
238000000338 in vitro Methods 0.000 description 20
230000014509 gene expression Effects 0.000 description 18
239000000523 sample Substances 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 16
239000002773 nucleotide Substances 0.000 description 15
239000002299 complementary DNA Substances 0.000 description 13
125000003729 nucleotide group Chemical group 0.000 description 13
238000001890 transfection Methods 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
108020004999 messenger RNA Proteins 0.000 description 10
238000003127 radioimmunoassay Methods 0.000 description 10
108010074604 Epoetin Alfa Proteins 0.000 description 9
229940089118 epogen Drugs 0.000 description 9
108700024394 Exon Proteins 0.000 description 8
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
238000012216 screening Methods 0.000 description 8
241000700605 Viruses Species 0.000 description 7
239000000047 product Substances 0.000 description 7
102000004594 DNA Polymerase I Human genes 0.000 description 6
108010017826 DNA Polymerase I Proteins 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000003623 enhancer Substances 0.000 description 6
239000003550 marker Substances 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 5
102000004142 Trypsin Human genes 0.000 description 5
108090000631 Trypsin Proteins 0.000 description 5
239000012141 concentrate Substances 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000000034 method Methods 0.000 description 5
230000010076 replication Effects 0.000 description 5
238000004007 reversed phase HPLC Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000012588 trypsin Substances 0.000 description 5
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
239000005862 Whey Substances 0.000 description 4
102000007544 Whey Proteins Human genes 0.000 description 4
108010046377 Whey Proteins Proteins 0.000 description 4
238000003556 assay Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000009021 linear effect Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
235000012054 meals Nutrition 0.000 description 4
238000012360 testing method Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
101150002621 EPO gene Proteins 0.000 description 3
108020005187 Oligonucleotide Probes Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
238000004166 bioassay Methods 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000003013 erythroid precursor cell Anatomy 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000002751 oligonucleotide probe Substances 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000009466 transformation Effects 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
244000286779 Hansenula anomala Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
NAXKFVIRJICPAO-LHNWDKRHSA-N [(1R,3S,4R,6R,7R,9S,10S,12R,13S,15S,16R,18S,19S,21S,22S,24S,25S,27S,28R,30R,31R,33S,34S,36R,37R,39R,40S,42R,44R,46S,48S,50R,52S,54S,56S)-46,48,50,52,54,56-hexakis(hydroxymethyl)-2,8,14,20,26,32,38,43,45,47,49,51,53,55-tetradecaoxa-5,11,17,23,29,35,41-heptathiapentadecacyclo[37.3.2.23,7.29,13.215,19.221,25.227,31.233,37.04,6.010,12.016,18.022,24.028,30.034,36.040,42]hexapentacontan-44-yl]methanol Chemical compound OC[C@H]1O[C@H]2O[C@H]3[C@H](CO)O[C@H](O[C@H]4[C@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]6[C@H](CO)O[C@H](O[C@H]7[C@H](CO)O[C@@H](O[C@H]8[C@H](CO)O[C@@H](O[C@@H]1[C@@H]1S[C@@H]21)[C@@H]1S[C@H]81)[C@H]1S[C@@H]71)[C@H]1S[C@H]61)[C@H]1S[C@@H]51)[C@H]1S[C@@H]41)[C@H]1S[C@H]31 NAXKFVIRJICPAO-LHNWDKRHSA-N 0.000 description 2
206010000269 abscess Diseases 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
238000006356 dehydrogenation reaction Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
244000005700 microbiome Species 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
125000000896 monocarboxylic acid group Chemical group 0.000 description 2
208000003154 papilloma Diseases 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
238000003466 welding Methods 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
XPBVBZPVNFIHOA-UVBJJODRSA-N Ala-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@H](C)N)=CNC2=C1 XPBVBZPVNFIHOA-UVBJJODRSA-N 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
102000016605 B-Cell Activating Factor Human genes 0.000 description 1
108010028006 B-Cell Activating Factor Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101100116570 Caenorhabditis elegans cup-2 gene Proteins 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
241001449342 Chlorocrambe hastata Species 0.000 description 1
244000163122 Curcuma domestica Species 0.000 description 1
235000003392 Curcuma domestica Nutrition 0.000 description 1
101150055350 DES gene Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108050009160 DNA polymerase 1 Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
101100116572 Drosophila melanogaster Der-1 gene Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283070 Equus zebra Species 0.000 description 1
241001131785 Escherichia coli HB101 Species 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241000230533 Gulo gulo Species 0.000 description 1
240000005979 Hordeum vulgare Species 0.000 description 1
235000007340 Hordeum vulgare Nutrition 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241000220225 Malus Species 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
241000282374 Puma concolor Species 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
229910001347 Stellite Inorganic materials 0.000 description 1
241001441724 Tetraodontidae Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000003373 anti-fouling effect Effects 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
AHICWQREWHDHHF-UHFFFAOYSA-N chromium;cobalt;iron;manganese;methane;molybdenum;nickel;silicon;tungsten Chemical compound C.[Si].[Cr].[Mn].[Fe].[Co].[Ni].[Mo].[W] AHICWQREWHDHHF-UHFFFAOYSA-N 0.000 description 1
238000013377 clone selection method Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
235000003373 curcuma longa Nutrition 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
108010092809 exonuclease Bal 31 Proteins 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229910052732 germanium Inorganic materials 0.000 description 1
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
235000013976 turmeric Nutrition 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LVP-93-500A 1984-12-04 1993-06-08 Method for the production of erytropoietin LV10505B (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US67781384A	1984-12-04	1984-12-04
US68862285A	1985-01-03	1985-01-03
US69325885A	1985-01-22	1985-01-22
PCT/US1985/002405 WO1986003520A1 (en)	1984-12-04	1985-12-03	Method for the production of erythropoietin

Publications (2)

Publication Number	Publication Date
LV10505A LV10505A (lv)	1995-02-20
LV10505B true LV10505B (en)	1996-04-20

Family

ID=27418329

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LVP-93-500A LV10505B (en)	1984-12-04	1993-06-08	Method for the production of erytropoietin
LVP-93-623A LV10507B (lv)	1984-12-04	1993-06-10	Vektors, šūnas, eritropoetins,farmaceitiskā kompozīcija

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LVP-93-623A LV10507B (lv)	1984-12-04	1993-06-10	Vektors, šūnas, eritropoetins,farmaceitiskā kompozīcija

Country Status (24)

Country	Link
EP (2)	EP0205564B2 (cs)
JP (4)	JPH02104284A (cs)
KR (1)	KR890001011B1 (cs)
AT (2)	ATE71408T1 (cs)
AU (1)	AU621535B2 (cs)
CA (1)	CA1341502C (cs)
CZ (3)	CZ281756B6 (cs)
DE (3)	DE3585161D1 (cs)
DK (4)	DK172953B1 (cs)
ES (1)	ES8800049A1 (cs)
FI (2)	FI104261B (cs)
GE (1)	GEP19970775B (cs)
GR (1)	GR852890B (cs)
HK (2)	HK105693A (cs)
HU (1)	HU216079B (cs)
IL (1)	IL77081A (cs)
LV (2)	LV10505B (cs)
MD (1)	MD1639C2 (cs)
NO (1)	NO304469B1 (cs)
PL (2)	PL154180B1 (cs)
PT (1)	PT81590B (cs)
SK (2)	SK168799A3 (cs)
UA (1)	UA44882C2 (cs)
WO (1)	WO1986003520A1 (cs)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4703008A (en) *	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) *	1983-12-13	1985-07-11	원본미기재	에리트로포이에틴의 제조방법
US4677195A (en) *	1985-01-11	1987-06-30	Genetics Institute, Inc.	Method for the purification of erythropoietin and erythropoietin compositions
DE3789678T2 (de) *	1986-02-27	1994-08-11	Snow Brand Milk Prod Co Ltd	Herstellung von erythropoietinproduzierenden Zellen und Verfahren zur Herstellung von Erythropoietin mit Verwendung dieser Zellen.
DK173067B1 (da) *	1986-06-27	1999-12-13	Univ Washington	Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
GB2197321B (en) *	1986-09-12	1990-10-03	Genentech Inc	Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
US4954437A (en) *	1986-09-15	1990-09-04	Integrated Genetics, Inc.	Cell encoding recombinant human erythropoietin
US4835260A (en) *	1987-03-20	1989-05-30	Genetics Institute, Inc.	Erythropoietin composition
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5888774A (en) *	1994-12-19	1999-03-30	Cangene Corporation	Recombinant DNA molecules and expression vectors for erythropoietin
KR100470180B1 (ko)	1995-06-15	2005-02-04	크루셀 홀란드 비.브이.	유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
EP0752474A1 (en)	1995-07-07	1997-01-08	Boehringer Mannheim Gmbh	Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
WO1997003200A1 (en) *	1995-07-07	1997-01-30	Boehringer Mannheim Gmbh	Nucleic acid coding for cmp-n-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
DE19535571A1 (de)	1995-09-14	1997-03-20	Boehringer Mannheim Gmbh	Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
US5952226A (en) *	1996-11-05	1999-09-14	Modex Therapeutiques	Hypoxia responsive EPO producing cells
NZ337465A (en)	1997-03-18	2002-04-26	Roche Diagnostics Gmbh	Pharmaceutical containing erythropoietin and iron preparations for treating haemodialysis patients or anaemias
EP0885613A1 (de)	1997-06-21	1998-12-23	Roche Diagnostics GmbH	Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
PT1000154E (pt)	1997-07-23	2007-03-30	Roche Diagnostics Gmbh	Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes
US6548296B1 (en)	1997-07-23	2003-04-15	Roche Diagnostics Gmbh	Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
ATE341625T1 (de) *	1997-07-23	2006-10-15	Roche Diagnostics Gmbh	Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
WO1999005267A1 (de) *	1997-07-23	1999-02-04	Roche Diagnostics Gmbh	Identifizierung humaner zellinien zur produktion humaner proteine durch endogene genaktivierung
US6391633B1 (en)	1997-07-23	2002-05-21	Roche Diagnostics Gmbh	Production of erythropoietin by endogenous gene activation
DE69726571T2 (de) *	1997-09-01	2004-11-04	Aventis Pharma Deutschland Gmbh	Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster
AR019025A1 (es)	1998-04-09	2001-12-26	Roche Diagnostics Gmbh	Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
BR9917606A (pt)	1998-11-06	2002-12-31	Bio Sidus S A	Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
BR9905868A (pt)	1998-11-06	2001-01-23	Bio Sidus S A	Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
US6777205B1 (en)	1998-11-06	2004-08-17	Sterrenbeld Biotechnologie North America, Inc.	Host cells expressing recombinant human erythropoietin
BR9905867A (pt)	1998-11-06	2001-01-23	Bio Sidus S A	Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
DE19857609A1 (de)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6855544B1 (en)	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
US7604960B2 (en)	1999-04-15	2009-10-20	Crucell Holland B.V.	Transient protein expression methods
US8236561B2 (en)	1999-04-15	2012-08-07	Crucell Holland B.V.	Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en)	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7527961B2 (en)	1999-11-26	2009-05-05	Crucell Holland B.V.	Production of vaccines
US7192759B1 (en)	1999-11-26	2007-03-20	Crucell Holland B.V.	Production of vaccines
US7521220B2 (en)	1999-11-26	2009-04-21	Crucell Holland B.V.	Production of vaccines
EP1274720A4 (en)	2000-04-12	2004-08-18	Human Genome Sciences Inc	FUSION PROTEINS CONTAINING ALBUMIN
CA2431964C (en)	2000-12-20	2013-09-10	F. Hoffmann-La Roche Ag	Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
DE10112825A1 (de)	2001-03-16	2002-10-02	Fresenius Kabi De Gmbh	HESylierung von Wirkstoffen in wässriger Lösung
KR100505152B1 (ko) *	2001-09-10	2005-08-03	(주)가이아진	아스코르브산을 이용한 에리트로포이에틴의 생산방법
US6930086B2 (en)	2001-09-25	2005-08-16	Hoffmann-La Roche Inc.	Diglycosylated erythropoietin
JP4480398B2 (ja)	2001-12-07	2010-06-16	クルセルホランドベーヴェー	ウイルス、ウイルス分離株及びワクチンの製造方法
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
DE10209822A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung von Proteinen an ein modifiziertes Polysaccharid
RU2245720C2 (ru) *	2002-07-01	2005-02-10	Государственное учреждение Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии МЗ РФ	Способ восполнения кровопотери при операциях на легких у больных туберкулезом
DE10234192B4 (de)	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
US7459435B2 (en)	2002-08-29	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
MXPA05002594A (es)	2002-09-11	2005-05-27	Fresenius Kabi Gmbh	Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
ATE409048T1 (de)	2002-10-08	2008-10-15	Fresenius Kabi De Gmbh	Pharmazeutisch aktive oligosaccharid-conjugate
US7459436B2 (en)	2002-11-22	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
KR101183770B1 (ko)	2003-05-09	2012-09-17	크루셀 홀란드 비.브이.	Ｅ1-불멸화된 세포의 배양물 및 이로부터 생성 수율을 증가시키기 위한 동일물의 배양 방법
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
JP2007517769A (ja)	2003-09-29	2007-07-05	ウォーレンファーマシューティカルズ，インコーポレーテッド	敗血症および癒着形成の治療および予防のための組織保護性サイトカイン
DK1699915T3 (da)	2003-12-30	2010-09-13	Augustinus Bader	Anvendelse af erythropoietin til levervævsregenerering
DE102004063927A1 (de)	2004-01-23	2005-12-15	Epoplus Gmbh Co.Kg	Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
ES2390885T3 (es)	2004-03-11	2012-11-19	Fresenius Kabi Deutschland Gmbh	Conjugados de hidroxialquilalmidón y una proteína
AR048035A1 (es)	2004-03-11	2006-03-22	Fresenius Kabi De Gmbh	Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
GB0507123D0 (en) *	2005-04-08	2005-05-11	Isis Innovation	Method
EP1762250A1 (en)	2005-09-12	2007-03-14	Fresenius Kabi Deutschland GmbH	Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
AR053416A1 (es) *	2005-11-10	2007-05-09	Protech Pharma S A	Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
EP1978030A4 (en)	2006-01-18	2009-12-30	Chugai Pharmaceutical Co Ltd	PROCESS FOR REMOVING SIALIC ACID AND METHOD FOR PRODUCING ASIALOERYTHROPOIETIN
DE102006004008A1 (de)	2006-01-27	2007-08-02	Hannelore Prof. Dr. Dr. Ehrenreich	Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
EP1991569A4 (en) *	2006-03-07	2009-12-23	Regenetech Inc	MAMMALIAN BIOLOGICAL MOLECULES WITH NATURAL GLYCOSYLATION PRODUCED BY ELECTROMAGNETIC STIMULATION OF LIVING MAMMALIAN CELLS
EP1997505A4 (en)	2006-03-22	2013-02-13	Chugai Pharmaceutical Co Ltd	PREPARATION OF A ERYTHROPOETIN SOLUTION
WO2008019214A1 (en)	2006-08-04	2008-02-14	Prolong Pharmaceuticals, Inc.	Modified erythropoietin
WO2009010107A1 (en)	2007-07-19	2009-01-22	Hannelore Ehrenreich	Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
EP2070950A1 (en)	2007-12-14	2009-06-17	Fresenius Kabi Deutschland GmbH	Hydroxyalkyl starch derivatives and process for their preparation
EP2095829A1 (en)	2008-02-27	2009-09-02	LEK Pharmaceuticals D.D.	Selenium containing modifying agents and conjugates
DE102008002209A1 (de)	2008-06-04	2009-12-10	Evonik Degussa Gmbh	Verfahren zur Aufreinigung von Erythropoietin
DE102008002210A1 (de)	2008-06-04	2009-12-10	Evonik Degussa Gmbh	Verfahren zur fermentativen Herstellung von Erythropoietin
EP2334699B1 (en)	2008-09-23	2013-09-11	F. Hoffmann-La Roche AG	Purification of erythropoietin
DE102008054716A1 (de)	2008-12-16	2010-06-17	Evonik Degussa Gmbh	Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
US20100272816A1 (en)	2009-04-27	2010-10-28	Wolfgang Rudinger	Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
EA022396B1 (ru)	2009-09-23	2015-12-30	Ратиофарм Гмбх	Способ очистки рекомбинантного эритропоэтина человека (epo), эритропоэтин, очищенный данным способом, и фармацевтические композиции, содержащие такой эритропоэтин
WO2017068051A1 (en)	2015-10-21	2017-04-27	Lek Pharmaceuticals D.D.	Peg-based dendron and process for producing the same
CN106906359B (zh)	2015-12-22	2018-12-11	理查德.亨威克	从硅酸盐矿物收取锂
EP3570871B1 (en)	2017-03-20	2020-11-18	H. Hoffnabb-La Roche Ag	Method for in vitro glycoengineering of an erythropoiesis stimulating protein
WO2022159414A1 (en)	2021-01-22	2022-07-28	University Of Rochester	Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US439780A (en) *		1890-11-04		Method of and apparatus for casting ingots
US3865801A (en) *	1973-06-15	1975-02-11	Atomic Energy Commission	Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
JPS5455790A (en) *	1977-10-05	1979-05-04	Tomoyuki Tajima	Production of erythropoetin
JPS5653696A (en) *	1979-10-09	1981-05-13	Ajinomoto Co Inc	Isolation of erythropoietin by adsorption
JPS6045849B2 (ja) *	1980-08-25	1985-10-12	林原健	ヒトエリトロポエチンの製造方法
US4419446A (en) *	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
JPS6043395A (ja) *	1983-08-19	1985-03-07	Sumitomo Chem Co Ltd	エリスロポエチンの製造法
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IT1185503B (it) *	1984-01-11	1987-11-12	Univ New York	Cloni di odna di eritropietina umana
JPS60215632A (ja) *	1984-04-12	1985-10-29	Japan Found Cancer	エリスロポエチンの製造法
US4732889A (en) *	1985-02-06	1988-03-22	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
JPH062070B2 (ja) *	1988-07-06	1994-01-12	農林水産省食品総合研究所長	▲ｏ下−▼アシルアミノ酸の製造方法

1985
- 1985-11-18 IL IL7708185A patent/IL77081A/en not_active IP Right Cessation
- 1985-12-02 GR GR852890A patent/GR852890B/el unknown
- 1985-12-02 PT PT81590A patent/PT81590B/pt unknown
- 1985-12-03 PL PL1985256589A patent/PL154180B1/pl unknown
- 1985-12-03 SK SK1687-99A patent/SK168799A3/sk unknown
- 1985-12-03 AT AT90118215T patent/ATE71408T1/de not_active IP Right Cessation
- 1985-12-03 DE DE9090118215T patent/DE3585161D1/de not_active Expired - Lifetime
- 1985-12-03 CZ CS858804A patent/CZ281756B6/cs not_active IP Right Cessation
- 1985-12-03 EP EP86900439A patent/EP0205564B2/en not_active Expired - Lifetime
- 1985-12-03 PL PL1985287787A patent/PL157926B1/pl unknown
- 1985-12-03 AU AU53134/86A patent/AU621535B2/en not_active Withdrawn - After Issue
- 1985-12-03 ES ES549539A patent/ES8800049A1/es not_active Expired
- 1985-12-03 WO PCT/US1985/002405 patent/WO1986003520A1/en not_active Ceased
- 1985-12-03 AT AT86900439T patent/ATE63137T1/de not_active IP Right Cessation
- 1985-12-03 DE DE199090118215T patent/DE411678T1/de active Pending
- 1985-12-03 SK SK8804-85A patent/SK279765B6/sk unknown
- 1985-12-03 GE GEAP19851901A patent/GEP19970775B/en unknown
- 1985-12-03 CA CA000496740A patent/CA1341502C/en not_active Expired - Fee Related
- 1985-12-03 EP EP90118215A patent/EP0411678B2/en not_active Expired - Lifetime
- 1985-12-03 HU HU553/86A patent/HU216079B/hu unknown
- 1985-12-03 DE DE8686900439T patent/DE3582732D1/de not_active Expired - Lifetime
1986
- 1986-07-24 FI FI863044A patent/FI104261B/fi not_active IP Right Cessation
- 1986-07-28 NO NO863050A patent/NO304469B1/no not_active IP Right Cessation
- 1986-08-01 DK DK198603687A patent/DK172953B1/da not_active IP Right Cessation
- 1986-08-04 KR KR8670525A patent/KR890001011B1/ko not_active Expired
1988
- 1988-03-18 JP JP63065592A patent/JPH02104284A/ja active Pending
- 1988-03-18 JP JP63065591A patent/JPH0655144B2/ja not_active Expired - Lifetime
- 1988-08-09 JP JP63198766A patent/JPH02442A/ja active Pending
1991
- 1991-11-15 UA UA5010104A patent/UA44882C2/uk unknown
1992
- 1992-12-02 JP JP4323466A patent/JPH07184681A/ja active Pending
1993
- 1993-06-08 LV LVP-93-500A patent/LV10505B/lv unknown
- 1993-06-10 LV LVP-93-623A patent/LV10507B/lv unknown
- 1993-10-07 HK HK1056/93A patent/HK105693A/en not_active IP Right Cessation
- 1993-10-07 HK HK1055/93A patent/HK105593A/en not_active IP Right Cessation
1994
- 1994-07-14 MD MD94-0371A patent/MD1639C2/ro not_active IP Right Cessation
1996
- 1996-05-02 CZ CZ19961274A patent/CZ286557B6/cs not_active IP Right Cessation
1997
- 1997-08-20 DK DK95197A patent/DK173254B1/da not_active IP Right Cessation
1999
- 1999-08-20 DK DK199901147A patent/DK173293B1/da not_active IP Right Cessation
- 1999-09-27 FI FI992064A patent/FI105347B/fi not_active IP Right Cessation
- 1999-12-02 CZ CZ19994314A patent/CZ287620B6/cs not_active IP Right Cessation
2000
- 2000-03-29 DK DK200000527A patent/DK175826B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
LV10507B (lv)	1996-06-20
JPH02104284A (ja)	1990-04-17
JPH07184681A (ja)	1995-07-25
DK173254B1 (da)	2000-05-22
SK281799B6 (sk)	2001-08-06
CZ287620B6 (cs)	2001-01-17
IL77081A (en)	1999-10-28
NO304469B1 (no)	1998-12-21
DK95197A (da)	1997-08-20
ES8800049A1 (es)	1987-10-16
DE3585161D1 (de)	1992-02-20
EP0205564A1 (en)	1986-12-30
ATE71408T1 (de)	1992-01-15
CZ281756B6 (cs)	1997-01-15
ATE63137T1 (de)	1991-05-15
EP0411678B2 (en)	2000-01-12
LV10505A (lv)	1995-02-20
SK880485A3 (en)	1999-03-12
JPH0655144B2 (ja)	1994-07-27
DK172953B1 (da)	1999-10-18
EP0411678B1 (en)	1992-01-08
DK199901147A (da)	1999-08-20
LV10507A (lv)	1995-02-20
PL157926B1 (pl)	1992-07-31
DK175826B1 (da)	2005-03-14
GR852890B (cs)	1986-04-03
AU621535B2 (en)	1992-03-19
CA1341502C (en)	2006-03-21
HUT40706A (en)	1987-01-28
KR890001011B1 (en)	1989-04-18
IL77081A0 (en)	1986-04-29
FI19992064L (fi)	1999-09-27
GEP19970775B (en)	1997-01-27
FI863044A0 (fi)	1986-07-24
EP0205564B2 (en)	2000-06-21
NO863050D0 (no)	1986-07-28
HU216079B (hu)	1999-04-28
CZ127496A3 (cs)	2000-02-16
WO1986003520A1 (en)	1986-06-19
DK368786D0 (da)	1986-08-01
AU5313486A (en)	1986-07-01
HK105593A (en)	1993-10-15
MD940371A (en)	1996-06-28
PT81590A (en)	1986-01-01
ES549539A0 (es)	1987-10-16
EP0411678A1 (en)	1991-02-06
DE3582732D1 (de)	1991-06-06
KR870700099A (ko)	1987-02-28
CZ286557B6 (cs)	2000-05-17
FI863044L (fi)	1986-07-24
FI104261B1 (fi)	1999-12-15
DK200000527A (da)	2000-03-29
DK368786A (da)	1986-08-01
CZ880485A3 (en)	1996-08-14
PL256589A1 (en)	1986-10-21
UA44882C2 (uk)	2002-03-15
SK279765B6 (sk)	1999-03-12
MD1639C2 (ro)	2001-10-31
EP0205564A4 (en)	1987-12-14
JPH02442A (ja)	1990-01-05
JPH01257480A (ja)	1989-10-13
MD1639B2 (en)	2001-03-31
NO863050L (no)	1986-07-28
EP0205564B1 (en)	1991-05-02
DE411678T1 (de)	1991-10-17
PL154180B1 (en)	1991-07-31
FI105347B (fi)	2000-07-31
HK105693A (en)	1993-10-15
DK173293B1 (da)	2000-06-13
FI104261B (fi)	1999-12-15
PT81590B (pt)	1987-10-20
SK168799A3 (en)	2001-08-06

Publication	Publication Date	Title
LV10507B (lv)	1996-06-20	Vektors, šūnas, eritropoetins,farmaceitiskā kompozīcija
EP0830376B1 (de)	2004-01-21	Verfahren zur herstellung von erythropoietin frei von tierischen proteinen
DE3880922T2 (de)	1993-08-26	Faktor viii-analog, verfahren zu dessen herstellung und dieses enthaltende zusammensetzung.
DE69404401T2 (de)	1998-02-19	Erythropoietin-Analoga mit zusätzlichen Glycosylierungsstellen
DE68926892T3 (de)	2000-11-09	Verfahren zur Herstellung von Zellen, die stabil integrierte fremde DNS mit hoher Kopiezahl enthalten, durch dieses Verfahren hergestellte Zellen und Verwendung dieser Zellen zur Herstellung von durch diese fremde DNS kodierten Polypeptiden
DE3788289T2 (de)	1994-06-23	Rekombinanter Proteinkomplex mit Humanfaktor-VIII:C-Aktivität, seine Herstellung und Anwendung.
DE3650774T2 (de)	2003-05-28	Rekombinante Fibroblasten-Wachstums-Faktoren
DE69023416T2 (de)	1996-06-27	Verwendung von il-7 bei arzneimitteln zur steigerung der plättchenherstellung.
DE69030740T2 (de)	1997-11-27	Rekombinantes DNS-Verfahren und Wirtszellen
DE3486469T2 (de)	1999-04-15	Herstellung heterodimirer menschlicher Fruchtbarkeitshormone
DE68928718T2 (de)	1998-10-29	Human-Nervenwachstumsfaktor
DE3884776T2 (de)	1994-02-10	Durch "site-directed" Mutagenese modifzierte Glukoprotein-Hormone und Verfahren zu deren Verwendung.
AT389892B (de)	1990-02-12	Dna-sequenz mit einem gen, das fuer human-interleukin-2 codiert
DE69227589T2 (de)	1999-04-08	Ecdysteroid-abhängige gen regulierung in säugetier-zellen
SK46598A3 (en)	2000-05-16	Recombinant dna plasmid vector, mammalian cell transformed with this vector, recombinant human erythropoietin, and method of its production
DE69034104T2 (de)	2004-04-08	Herstellung von heteropolymeren Proteinen
DD251788A5 (de)	1987-11-25	Verfahren zur Herstellung eines menschlichen cDNA-Klons
EP0256302B1 (de)	1993-02-03	Verfahren zur Herstellung von humanem Antithrombin-III (ATIII) und dafür geeignete Vektoren
DD279687A5 (de)	1990-06-13	Verfahren zur herstellung von erythropoietin
DE68909617T2 (de)	1994-02-10	Verfahren zur herstellung von proteinen mit fviii aktivität und/oder fviii derivate.
AU5711199A (en)	2000-01-13	Method for the production of erythropoietin
DD255359A5 (de)	1988-03-30	Verfahren zur bestimmung eines spezifischen einzelstraengigen polynuclebtids unbekannter sequenz
DD251786A5 (de)	1987-11-25	Verfahren zur Herstellung eines Polypeptids
DE10152660A1 (de)	2002-05-23	Verwendung einer Nukleotidsequenz kodierend für ein intrazelluläres Hyaluronsäure-bindendes Protein